2 July 2021Prescribers may need to choose a safe antidepressant in people with CHD. We guide on available options. We do not cover management of complex depression.
21 October 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Monamine-oxidase inhibitors (MAOIs) Due to the…
22 May 2020This Medicines Q&A outlines the causes and symptoms of serotonin syndrome and provides examples of medicines with the potential to cause serotonin syndrome.
21 October 2019This updated Medicines Q&A provides advice on the risks and suggested strategies for switching between tricyclic (TCA), selective serotonin reuptake inhibitors (SSRI) and related antidepressants.…
10 June 2019This Medicines Q&A evaluates the evidence available on the management of depression in patients with antidepressant-induced hyponatraemia. Summary Most antidepressants are associated with hyponatraemia, with…
Medicine Compliance Aid Stability
SinepinMarlborough Pharmaceuticals Ltd
Marlborough Pharmaceuticals Ltd
Capsules 25mg, 50mg
A3 · Amber 3 No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from moisture. Protect from light.
26 October 2015
Lactation Safety Information
Very limited published evidence of safety indicates small but significant amounts in breast milk
Serious adverse effects reported in breast fed infant
4 August 2020
No published evidence of safety
Serious adverse effects reported in breastfed infant after oral doxepin
Risk from topical application cannot be excluded due to possible significant systemic absorption by the mother
Avoid use where possible
If use is clinically justified, do not apply to any part of the breast
30 October 2020